ESMO Virtual Advanced Course on
Cancer Vaccines and Cellular Immunotherapy
29-30 April 2022

CO-CHAIRS: Andrew Furness, United Kingdom
Pedro Romero, Switzerland

SPEAKERS: Johanna Joyce, Switzerland
Mark Middleton, United Kingdom
Emma Nicholson, UK
Patrick Ott, United States
Antoni Ribas, United States
Claire Ruddle, United Kingdom
Inge-Marie Svane, Denmark

LEARNING OBJECTIVES

- To acquire insights in the preclinical and clinical development of vaccines and cellular immunotherapeutic approaches against cancer
- To learn about advances and ongoing research in optimal combinations of immunotherapeutic approaches involving vaccines and cell effectors, along with prognostic and predictive biomarkers
- To obtain in-depth understanding of perspectives, bottlenecks and unmet needs in the evolving field of cancer vaccines and cellular immunotherapies

Programme timings are to be considered CEST (Central European Summer Time)

Friday, 29 April 2022

15:00 – 15:10 Welcome and course overview
10’ Andrew Furness and Pedro Romero

15:10 – 16:25 Session 1 – Insights and ongoing research in the understanding of anti tumour immune response: effectors, modulators, microenvironment and tumour evasion
20’ Challenges of the tumour microenvironment
Johanna Joyce, CH

20’ Adaptive immunity
TBC

20’ Immune evasion
Antoni Ribas, US
15’ Discussion
Faculty

16:25 - 16:40 Virtual break

16:40 - 17:55 Session 2 - Therapeutic strategies based on cellular effectors of anti tumour immune response

20’ Tumour infiltrating lymphocyte therapy
Andrew Furness, UK

20’ T-cell receptor therapy
TBC

20’ CAR-T cell therapy
Claire Roddie, UK

15’ Discussion
Faculty

17:55 - 19:10 Session 3 - Preclinical and clinical development of cancer vaccines

20’ Preclinical development of cancer vaccines
Pedro Romero, CH

20’ Clinical development of personalised cancer vaccines
Patrick Ott

20’ Combination of cancer vaccines with other immunotherapies
TBC

15’ Discussion
Faculty
**Saturday, 30 April 2022**

15:00 - 18:15  **Workshops sessions** (all delegates will attend all workshops, one after the other)
   
   10’ Introduction based on clinical cases presented by speakers (*3 clinical cases*)
   
   20’ Discussion for each clinical case

15:00 - 16:30  **Workshop 1 – Cancer vaccines**
   
   - First clinical case: mRNA vaccines (TBC)
   - Second clinical case: Synthetic peptides (Patrick Ott, US)
   - Third clinical case: Recombinant vectors (Mark Middleton, UK)

16:30 - 16:45  **Virtual break**

16:45 - 18:15  **Workshop 2 – Cell therapy**
   
   - First clinical case: TIL therapy (Inge-Marie Svane, DK)
   - Second clinical case: TCR (TBC)
   - Third clinical case: CAR-T (Emma Nicholson, UK)

18:15 - 18:30  **Synthesis and wrap-up**

15’  Andrew Furness, UK